Assertio Therapeutics Current Valuation vs. EBITDA

ASRT Stock  USD 0.96  0.04  4.00%   
Based on Assertio Therapeutics' profitability indicators, Assertio Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Assertio Therapeutics' ability to earn profits and add value for shareholders. Operating Cash Flow Sales Ratio is likely to gain to 0.34 in 2024, whereas Price To Sales Ratio is likely to drop 0.47 in 2024. At this time, Assertio Therapeutics' Income Tax Expense is comparatively stable compared to the past year. Net Income Applicable To Common Shares is likely to gain to about 103.6 M in 2024, despite the fact that Net Loss is likely to grow to (315.3 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.320.8223
Way Up
Pretty Stable
For Assertio Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Assertio Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Assertio Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Assertio Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Assertio Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assertio Therapeutics. If investors know Assertio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assertio Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.19)
Earnings Share
(4.94)
Revenue Per Share
1.322
Quarterly Revenue Growth
(0.18)
Return On Assets
(0.01)
The market value of Assertio Therapeutics is measured differently than its book value, which is the value of Assertio that is recorded on the company's balance sheet. Investors also form their own opinion of Assertio Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Assertio Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assertio Therapeutics' market value can be influenced by many factors that don't directly affect Assertio Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assertio Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assertio Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assertio Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Assertio Therapeutics EBITDA vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Assertio Therapeutics's current stock value. Our valuation model uses many indicators to compare Assertio Therapeutics value to that of its competitors to determine the firm's financial worth.
Assertio Therapeutics is rated below average in current valuation category among its peers. It is rated below average in ebitda category among its peers . At this time, Assertio Therapeutics' EBITDA is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Assertio Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Assertio Current Valuation vs. Competition

Assertio Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is presently estimated at about 73.74 Billion. Assertio Therapeutics adds roughly 46.51 Million in current valuation claiming only tiny portion of equities under Health Care industry.

Assertio EBITDA vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Assertio Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
46.51 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Assertio Therapeutics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(222.45 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Assertio EBITDA Comparison

Assertio Therapeutics is currently under evaluation in ebitda category among its peers.

Assertio Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Assertio Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Assertio Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Assertio Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Assertio Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-10.7 M-10.1 M
Operating Income-243.5 M-231.4 M
Net Loss-331.9 M-315.3 M
Income Tax Expense77.9 M81.8 M
Income Before Tax-254.1 M-241.4 M
Total Other Income Expense Net-10.5 M-10 M
Net Income Applicable To Common Shares98.7 M103.6 M
Net Loss-331.9 M-315.3 M
Non Operating Income Net Other34.9 M36.6 M
Interest Income49 M51.4 M
Net Interest Income-13.3 M-14 M
Change To Netincome-59.5 M-56.5 M
Net Loss(4.67)(4.44)
Income Quality(0.15)(0.14)
Net Income Per E B T 1.31  1.19 

Assertio Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Assertio Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Assertio Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Assertio Therapeutics' important profitability drivers and their relationship over time.

Use Assertio Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Assertio Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Assertio Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Assertio Therapeutics Pair Trading

Assertio Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Assertio Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Assertio Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Assertio Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Assertio Therapeutics to buy it.
The correlation of Assertio Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Assertio Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Assertio Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Assertio Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Assertio Therapeutics position

In addition to having Assertio Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Hybrid Mix Funds Thematic Idea Now

Hybrid Mix Funds
Hybrid Mix Funds Theme
Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.